116 related articles for article (PubMed ID: 19524318)
1. Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).
Li T; Ho L; Piperdi B; Elrafei T; Camacho FJ; Rigas JR; Perez-Soler R; Gucalp R
Lung Cancer; 2010 Apr; 68(1):89-93. PubMed ID: 19524318
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer.
Scagliotti GV; Germonpré P; Bosquée L; Vansteenkiste J; Gervais R; Planchard D; Reck M; De Marinis F; Lee JS; Park K; Biesma B; Gans S; Ramlau R; Szczesna A; Makhson A; Manikhas G; Morgan B; Zhu Y; Chan KC; von Pawel J
Lung Cancer; 2010 Jun; 68(3):420-6. PubMed ID: 19692142
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of carboplatin/paclitaxel/bortezomib and concurrent radiotherapy followed by surgical resection in Stage III non-small cell lung cancer.
Edelman MJ; Burrows W; Krasna MJ; Bedor M; Smith R; Suntharalingam M
Lung Cancer; 2010 Apr; 68(1):84-8. PubMed ID: 19540615
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.
Davis NB; Taber DA; Ansari RH; Ryan CW; George C; Vokes EE; Vogelzang NJ; Stadler WM
J Clin Oncol; 2004 Jan; 22(1):115-9. PubMed ID: 14701773
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer.
Peschel C; Hartmann JT; Schmittel A; Bokemeyer C; Schneller F; Keilholz U; Buchheidt D; Millan S; Izquierdo MA; Hofheinz RD
Lung Cancer; 2008 Jun; 60(3):374-80. PubMed ID: 18054408
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of oral topotecan in advanced non-small cell lung cancer.
White SC; Cheeseman S; Thatcher N; Anderson H; Carrington B; Hearn S; Ross G; Ranson M
Clin Cancer Res; 2000 Mar; 6(3):868-73. PubMed ID: 10741709
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
Markovic SN; Geyer SM; Dawkins F; Sharfman W; Albertini M; Maples W; Fracasso PM; Fitch T; Lorusso P; Adjei AA; Erlichman C
Cancer; 2005 Jun; 103(12):2584-9. PubMed ID: 15887220
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
[TBL] [Abstract][Full Text] [Related]
9. Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer.
Oh Y; Herbst RS; Burris H; Cleverly A; Musib L; Lahn M; Bepler G
J Clin Oncol; 2008 Mar; 26(7):1135-41. PubMed ID: 18309949
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.
Fanucchi MP; Fossella FV; Belt R; Natale R; Fidias P; Carbone DP; Govindan R; Raez LE; Robert F; Ribeiro M; Akerley W; Kelly K; Limentani SA; Crawford J; Reimers HJ; Axelrod R; Kashala O; Sheng S; Schiller JH
J Clin Oncol; 2006 Nov; 24(31):5025-33. PubMed ID: 17075122
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.
Leighl NB; Paz-Ares L; Douillard JY; Peschel C; Arnold A; Depierre A; Santoro A; Betticher DC; Gatzemeier U; Jassem J; Crawford J; Tu D; Bezjak A; Humphrey JS; Voi M; Galbraith S; Hann K; Seymour L; Shepherd FA
J Clin Oncol; 2005 Apr; 23(12):2831-9. PubMed ID: 15837997
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors.
Shah MH; Young D; Kindler HL; Webb I; Kleiber B; Wright J; Grever M
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6111-8. PubMed ID: 15447997
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer.
Okamoto I; Moriyama E; Fujii S; Kishi H; Nomura M; Goto E; Kiyofuji C; Imamura F; Mori T; Matsumoto M
Jpn J Clin Oncol; 2005 Apr; 35(4):188-94. PubMed ID: 15845567
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
Chen CI; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E;
J Clin Oncol; 2007 Apr; 25(12):1570-5. PubMed ID: 17353550
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer.
Langer CJ; Leighton J; McAleer C; Comis R; O'Dwyer P; Ozols R
Semin Oncol; 1995 Jun; 22(3 Suppl 6):64-9. PubMed ID: 7541156
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer.
Besse B; Planchard D; Veillard AS; Taillade L; Khayat D; Ducourtieux M; Pignon JP; Lumbroso J; Lafontaine C; Mathiot C; Soria JC
Lung Cancer; 2012 Apr; 76(1):78-83. PubMed ID: 22186627
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.
Davies AM; Ho C; Metzger AS; Beckett LA; Christensen S; Tanaka M; Lara PN; Lau DH; Gandara DR
J Thorac Oncol; 2007 Dec; 2(12):1112-6. PubMed ID: 18090584
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies.
Kubicek GJ; Axelrod RS; Machtay M; Ahn PH; Anne PR; Fogh S; Cognetti D; Myers TJ; Curran WJ; Dicker AP
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1192-7. PubMed ID: 22245208
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of S-1 monotherapy in platinum-refractory, advanced non-small cell lung cancer.
Shiroyama T; Komuta K; Imamura F; Hirashima T; Kijima T; Tachibana I; Kawase I
Lung Cancer; 2011 Oct; 74(1):85-8. PubMed ID: 21342712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]